Table 2. Characteristics of included studies for refractive error.
| Study | Study Type | Number of eyes | Intervention | Follow-Up (months)* | Refractive Error | Refractive Error |
|---|---|---|---|---|---|---|
| Sphere | Cylinder | |||||
| Chen, 2014 [21] | retrospective | 40 | Bevacizumab | 24 | 0.98 | 2.23 |
| 17 | Bevacizumab with laser coagulation | 24 | -2.4 | 2.23 | ||
| Geloneck, 2014 [23] | Follow-Up of | 110 | Bevacizumab | 30 | -1,02 | |
| Mintz-Hittner (38) | 101 | Laser coagulation | 30 | -6,73 | ||
| Harder, 2013 [32] | retrospective | 23 | Bevacizumab | 12 | 0 | -1 |
| 26 | Laser coagulation | 12 | -5.5 | 1.5 | ||
| Harder, 2012 [37] | prospective, | 12 | Bevacizumab | - | 0.635 | 1.015 |
| non-randomized | 20 | Laser coagulation | - | -5.225 | 1.69 | |
| Axer-Siegel, 2011 [38] | retrospective | 10 | Bevacizumab | - | 0.5 | 0.5 |
| 8 | Bevacizumab with laser coagulation | - | -7.25 | 0 | ||
| Mintz-Hittner, 2011 [40] | prospective, | 140 | Bevacizumab | 12 | 0.99 | - |
| randomized | 146 | Laser coagulation | 12 | 7.01 | - |
Studies are sorted by date of publication.
*The follow-up period is only reported if follow-up was a defined period of time.